Streetbeat News

Analyst Ratings

SR

Mizuho analyst Gabriel Moreen has maintained a Buy rating on Spire Inc. (NYSE:SR) but has reduced the price target from $66 to $64.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:23 pm

CYTK

Mizuho analyst Salim Syed has reaffirmed a Buy rating on Cytokinetics (NASDAQ:CYTK) and increased the price target from $80 to $103, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:17 pm

ADMA

Mizuho analyst Anthony Petrone has reaffirmed a Buy rating on ADMA Biologics (NASDAQ:ADMA) and increased the price target from $7 to $9, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:15 pm

CART

Benchmark analyst Mark Zgutowicz has initiated coverage on Maplebear, trading under the ticker CART on NASDAQ, with a Buy rating and a price target of $32.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:09 pm

DISH

SATS

The Buxton Helmsley Group, Inc. (BHG), an investment fund manager, issued a letter to EchoStar Corporation's Board of Directors alleging accounting and securities fraud, fraudulent conveyances, and breaches of fiduciary duty related to EchoStar's recent merger with DISH Network Corp. BHG claims that DISH had pre-merger material misstatements of financial position and that EchoStar did not respond to BHG's private notification of these issues. BHG holds a short interest in the securities of both companies and may adjust its positions in the future.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:05 pm

COMS

ThinkEquity analyst Ashok Kumar has initiated coverage on ComSovereign Holding (NASDAQ:COMS) with a Buy rating and set a price target of $3 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:03 pm

CNP

Barclays analyst Eric Beaumont has maintained an Underweight rating on CenterPoint Energy (NYSE:CNP) but increased the price target from $27 to $28.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:02 pm

EYPT

EyePoint Pharmaceuticals (NASDAQ:EYPT) has been evaluated by 7 analysts over the last three months, with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $31.71, up 18.54% from the previous $26.75, with a high estimate of $44.00 and a low of $20.00. Recent analyst actions include ratings and price target adjustments by JP Morgan, HC Wainwright & Co., Capital One, and Mizuho. EyePoint Pharmaceuticals focuses on ophthalmic products and has shown a revenue growth of 51.84% as of September 30, 2023. However, it has a net margin of -82.96% and an ROE of -21.77%, indicating profitability challenges.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 2:01 pm

WDAY

Workday (NASDAQ:WDAY) has been the subject of 20 analyst ratings over the past three months, with sentiments ranging from bullish to bearish. The average 12-month price target for WDAY is $286.7, with a high of $330.00 and a low of $245.00, indicating an 11.66% increase from the previous average of $256.76. Analysts have recently adjusted their ratings and price targets, with many maintaining or raising their outlooks. Workday's financial performance shows strong revenue growth but below-average net margin, ROE, and ROA, with a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 2:01 pm

RIOT

Riot Platforms (NASDAQ:RIOT), a vertically integrated Bitcoin mining company, has received mixed analyst ratings over the past quarter, with 2 bullish and 4 somewhat bullish ratings. The average 12-month price target is $19.18, up from the previous $18.75. Analysts from firms like Cantor Fitzgerald, Roth MKM, HC Wainwright & Co., and Bernstein have maintained or raised their price targets, reflecting a positive outlook on the company's performance. Despite a strong market capitalization and exceptional ROE, Riot Platforms faces challenges with a net margin of -87.35% and an ROA of -3.22%, indicating profitability issues.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 2:01 pm